Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 246

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

Open access
Zhu, Andrew X., Stuart, Keith, Blaszkowsky, Lawrence S., Muzikansky, Alona, Reitberg, Donald P., Clark, Jeffrey W., Enzinger, Peter C., Bhargava, Pankaj, Meyerhardt, Jeffrey A., Horgan, Kerry, Fuchs, Charles S., Ryan, David P.·2007·Cancer

Abstract

BACKGROUND.: Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. METHODS.: Eligibility criteria included unresectable or metastatic measurable HCC, an Eastern Cooperative Oncology Group performance status ≤2, Cancer of the Liver Italian Program (CLIP) score ≤3, and adequate organ functions. The initial dose of cetuximab was 400 mg/m 2 given intravenously followed by weekly intravenous infusions at 250 mg/m 2. Each cycle was defined as 6 consecutive weekly treatments. EGFR expression was assayed by immunohistochemistry and trough serum concentrations of cetuximab were determined during the first cycle. RESULTS.: Thirty patients were enrolled and assessable for efficacy and toxicity. No responses were seen. Five patients had stable disease (median time, 4.2 months; range, 2.8–4.2 months). The median overall survival was 9.6 months (95% confidence interval [CI], 4.3–12.1 months) and the median progression‐free survival (PFS) was 1.4 months (95% CI, 1.2–2.6 months). The treatment was generally well tolerated. No treatment‐related grade 4–5 toxicities occurred. Grade 3 (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events [version 3.0]) aspartate aminotransferase, hypomagnesemia, and fever without neutropenia were noted in 1 patient (3.3%) each. On Week 6 of Cycle 1, arithmetic mean serum cetuximab concentrations for patients with Child‐Turcotte‐Pugh (CTP) A and CTP B disease were 47.6 mcg/mL and 66.9 mcg/mL, respectively. CONCLUSIONS.: Although cetuximab could be safely administered with tolerable toxicity profiles, it demonstrated no antitumor activity in HCC in this phase 2 study. Cetuximab trough concentrations were not notably altered in patients with mild to moderate hepatic dysfunction. © 2007 American Cancer Society. Cancer 2007. ©2007 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22829

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 246

Metadata

Authors
Zhu, A. X., Stuart, K., Blaszkowsky, L. S., Muzikansky, A., Reitberg, D. P., Clark, J. W., Enzinger, P. C., Bhargava, P., Meyerhardt, J. A., Horgan, K., Fuchs, C. S., & Ryan, D. P.
Venue
Cancer
Publisher
Wiley
Published
2007-06-21
Volume
110
Issue
3
Pages
581-589
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2020509813
Cited by
246
References
4
FWCI
19.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. https://app.cochat.ai/papers/10.1002/cncr.22829
The paper
Zhu, A. X., Stuart, K., Blaszkowsky, L. S., Muzikansky, A., Reitberg, D. P., Clark, J. W., Enzinger, P. C., Bhargava, P., Meyerhardt, J. A., Horgan, K., Fuchs, C. S., & Ryan, D. P. (2007). Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. https://doi.org/10.1002/cncr.22829

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.